New CRESTOR® (rosuvastatin calcium) Savings Card Program provides instant savings to patients

Monday, 7 November 2011

New Savings Card allows eligible patients to get CRESTOR for just $8 more than the average copay of a generic statin*

AstraZeneca (NYSE:AZN) today announced the launch of a new savings card which allows eligible patients to get their CRESTOR prescription for just $8 more than the average copay of a generic statin.1* Eligible patients can pay just $18 for a prescription of CRESTOR (up to 30 tablets). Full eligibility rules and restrictions are available at CRESTOR.com.

For commercially insured patients, the CRESTOR Savings Card offers savings on out-of-pocket costs that exceed $18 (up to a $50 savings limit) on each of eligible patients’ next 12 prescriptions for CRESTOR (up to 30 tablets). Patients with no insurance coverage will receive $50 off each of their next 12 prescriptions for CRESTOR (up to 30 tablets). Patients can obtain the new savings card by contacting their health care provider or downloading it at CRESTOR.com/savings. The savings card can be used immediately and requires no activation.

“At AstraZeneca, we never want cost to be a hurdle for patients,” said Philip de Vane, M.D., Executive Director of Clinical Development for CRESTOR. “Through programs like the CRESTOR savings card, along with our other patient assistance programs, we work to ensure that our medicines are available to patients who need them.”

Example of Savings on CRESTOR for Commercially Insured Patients

Prescription CopayEligibilityPatient PaysPatient Savings
$10 N $10 ---
$25 Y $18 $7
$50 Y $18 $32
$75 Y $25 $50

In adults, CRESTOR, along with diet, is proven to lower “bad” cholesterol by up to 52% (at the 10-mg dose versus 7% with placebo) and is also FDA-approved to slow plaque buildup in arteries, as part of a treatment plan to lower cholesterol to goal.2

CRESTOR is not right for everyone, including anyone who has previously had an allergic reaction to CRESTOR, anyone with liver problems, or women who are nursing, pregnant, or who may become pregnant. Please see additional important safety information below.

-ENDS-

*Based on the ‘average Tier 1 copay for Commercial covered lives’ for generic statins from Fingertip Formulary as of July 26, 2011.

NOTES TO EDITORS:

About CRESTOR® (rosuvastatin calcium) Tablets

When diet and exercise alone aren't enough, adding CRESTOR can help.

In adults, CRESTOR is prescribed along with diet to lower high cholesterol and to slow the buildup of plaque in the arteries as part of a treatment plan to lower cholesterol to goal.

Important Safety Information about CRESTOR® (rosuvastatin calcium) Tablets

CRESTOR is not right for everyone, including anyone who has previously had an allergic reaction to CRESTOR, anyone with liver problems, or women who are nursing, pregnant, or who may become pregnant. Your doctor should do blood tests before and during treatment with CRESTOR to monitor your liver function. Unexplained muscle pain or weakness could be a sign of a rare but serious side effect and should be reported to your doctor right away. Elevated blood sugar levels have been reported with statins, including CRESTOR. Be sure to tell your doctor if you are taking any medications. The most common side effects are headache, muscle aches, abdominal pain, weakness, and nausea.

Please read the full Prescribing Information.

If you have any questions concerning CRESTOR, please visit CRESTOR.com or contact AstraZeneca at 1-800-CRESTOR.

CRESTOR Savings Card Program

Patient Eligibility: This offer is good for qualified customers for the purchase of a 30-tablet supply of CRESTOR® (rosuvastatin calcium) Tablets and may not be used for any other product. This offer is good for up to 12 prescriptions of CRESTOR and expires 14 months from the time of first use. This offer is good for the purchase of CRESTOR manufactured for AstraZeneca Pharmaceuticals LP and lawfully purchased from an authorized retailer or distributor in the United States or Puerto Rico. This offer may not be combined with any other offer, including any coupon, discount, or prescription savings card program. It is void for mail order and is not valid for prescriptions purchased under Medicaid, Medicare, or similar federal or state programs, or if your insurance plan is paying the entire cost of the prescription. Offer is void in MA and where prohibited by law, taxed, or restricted. Please note that this offer is limited to one offer per person and is not transferable.

Patient Instructions: Offer must be presented along with a valid prescription for CRESTOR at the time of purchase. Commercially insured patients receive savings on out-of-pocket costs that exceed $18 (up to a $50 savings limit) on each of their next 12 prescriptions (up to 30 tablets) of CRESTOR. Savings not applicable to out-of-pocket costs of $18 or less. If you do not have prescription coverage, you will receive $50 savings off the total cost on each of your next 12 prescriptions (up to 30 tablets) of CRESTOR. This offer may be changed or discontinued at any time without notice.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

CRESTOR is a registered trademark, and AZ&Me is a trademark of the AstraZeneca group of companies. ©2011 AstraZeneca. All rights reserved. 1415409 9/11

Media Inquiries:

Rachelle Benson +1 302 885 5853 Rachelle.Benson@astrazeneca.com
Elizabeth Renz +1 302 885 1936 Elizabeth.Renz@astrazeneca.com

1 Data on File, 1403806, AstraZeneca Pharmaceuticals LP.
2 Prescribing information for CRESTOR

1415409 9/11


Please note

These press releases were issued in the United States (US) and are posted here as reference information for US investors and journalists only. The information contained in each press release was accurate at the time of issuance, and AstraZeneca assumes no responsibility for updating the information to reflect subsequent developments.

View information on AstraZeneca products, including their current US Prescribing Information.